Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by KCM Investment Advisors LLC

KCM Investment Advisors LLC decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 44.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 16,770 shares of the medical equipment provider’s stock after selling 13,368 shares during the period. KCM Investment Advisors LLC’s holdings in Zimmer Biomet were worth $1,508,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Cornerstone Financial Management LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth about $37,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Zimmer Biomet by 43.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 678,869 shares of the medical equipment provider’s stock worth $61,044,000 after buying an additional 205,257 shares during the period. Atlas Capital Advisors Inc. acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth about $262,000. Aptus Capital Advisors LLC boosted its stake in shares of Zimmer Biomet by 9.3% during the fourth quarter. Aptus Capital Advisors LLC now owns 6,333 shares of the medical equipment provider’s stock worth $569,000 after buying an additional 539 shares during the period. Finally, Kestra Advisory Services LLC boosted its stake in shares of Zimmer Biomet by 15.4% during the fourth quarter. Kestra Advisory Services LLC now owns 7,414 shares of the medical equipment provider’s stock worth $667,000 after buying an additional 992 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Trading Down 0.0%

NYSE ZBH opened at $88.54 on Monday. The stock has a market capitalization of $17.13 billion, a P/E ratio of 23.00, a P/E/G ratio of 2.05 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The firm has a 50-day moving average price of $87.56 and a 200 day moving average price of $90.41. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the prior year, the company posted $1.81 earnings per share. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Citigroup cut their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. Stifel Nicolaus cut their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Wells Fargo & Company cut their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, April 29th. Finally, BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $102.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.